Investigating the Mechanism of JC Polyomavirus Endocytosis by Lajoie, Conner Robert
The University of Maine
DigitalCommons@UMaine
Honors College
Spring 5-2017
Investigating the Mechanism of JC Polyomavirus
Endocytosis
Conner Robert Lajoie
University of Maine
Follow this and additional works at: https://digitalcommons.library.umaine.edu/honors
Part of the Biochemistry Commons, and the Molecular Biology Commons
This Honors Thesis is brought to you for free and open access by DigitalCommons@UMaine. It has been accepted for inclusion in Honors College by
an authorized administrator of DigitalCommons@UMaine. For more information, please contact um.library.technical.services@maine.edu.
Recommended Citation
Lajoie, Conner Robert, "Investigating the Mechanism of JC Polyomavirus Endocytosis" (2017). Honors College. 439.
https://digitalcommons.library.umaine.edu/honors/439
		
Investigating the mechanism of JC polyomavirus endocytosis 
By 
Conner Robert Lajoie 
 
 
 
 
 
 
A Thesis Submitted in Partial Fulfillment 
of the Requirements for a Degree with Honors 
(Biochemistry and Molecular & Cellular Biology) 
 
 
 
 
 
 
 
The Honors College 
University of Maine 
May 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Advisory Committee: 
         Melissa Maginnis, Ph.D., Assistant Professor of Microbiology, Advisor 
         Melissa Ladenheim, Ph.D., Associate Dean of the Honors College 
         Keith Hutchison, Ph.D., Professor Emeritus of Biochemistry and Molecular Biology 
         Sally Dixon Molloy, Ph.D., Assistant Professor of Genomics 
         Joshua Kelley, Ph.D., Assistant Professor of Biochemistry  
 
		ii	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2017 by Conner Robert Lajoie 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		iii	
ABSTRACT 
 
The majority of the human population is infected with JC polyomavirus (JCPyV), which 
establishes an asymptomatic infection in the kidney of healthy individuals. In 
immunosuppressed individuals, the virus spreads to the brain and attacks glial cells, 
causing progressive multifocal leukoencephalopathy (PML), a fatal demyelinating 
disease. With limited treatments available, an improved understanding of the virus-host 
cell interactions during JCPyV infection is crucial for developing effective PML 
therapies. JCPyV internalization into host cells requires the serotonin 5-
hydroxytryptamine type 2 (5-HT2) receptors. The mechanism by which the 5-HT2Rs 
mediate viral entry has not yet been characterized, yet it is thought to occur by clathrin-
mediated endocytosis (CME). The objective of this research is to determine whether key 
5-HT2R scaffolding proteins that mediate clathrin-dependent endocytosis are required for 
JCPyV infection. Reduction of cellular adaptor protein 2 (AP2), adaptor protein 180 
(AP180), and clathrin by siRNA significantly reduced JCPyV infection, yet inhibition of 
calmodulin using a chemical calmodulin inhibitor had minimal effect on JCPyV 
infection. Taken together, these findings suggest these specific 5-HT2R scaffolding 
proteins are crucial for JCPyV infection. Additionally, this research is not limited to our 
understanding of JCPyV viral pathogenesis, a significant human pathogen with the 
potential to cause fatality, but can also be applied to understanding other neurotropic 
viruses or other viruses that enter by CME. 
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Introduction 
Overview 
Opportunistic pathogens have become a major concern in the realm of infectious disease. 
These pathogens cause asymptomatic infections in healthy individuals and are capable of 
causing severe and life-threatening infections in patients who are immunosuppressed (1). 
JC polyomavirus (JCPyV) is an opportunistic pathogen that causes progressive multifocal 
leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system 
(CNS). Specifically, JCPyV causes cytolytic destruction of oligodendrocytes, the myelin-
producing cells of the CNS (2). PML has a fatality rate of 90% within the first two years 
of symptom onset (2). Currently, approximately 5% of individuals who are HIV-1+ are 
affected by PML (1), and in the past decade, the number of PML cases has risen to nearly 
1:500 in patients who are receiving natalizumab, an immunomodulatory therapy designed 
to treat immune-mediated diseases, such as multiple sclerosis (MS) and Crohn’s disease 
(1,2). Thus, as the number of individuals receiving immunomodulatory therapies 
increases with the rise of immune-related diseases, the incidence rate of PML is 
anticipated to also rise. PML is a severe, debilitating disease, with affected individuals 
experiencing deficiencies in cognitive functioning and developing symptoms such as 
paralysis (1). Unfortunately, there are currently no viable treatments for this disease.  
The limited treatment options for PML underscore the importance of 
understanding the crucial mechanisms of viral attachment and internalization that enable 
the virus to engage and initiate infection in target host cells. The goal of this research is to 
identify and characterize the role of the scaffolding proteins calmodulin, adaptor proteins 
2 (AP2) and 180 (AP180), b-arrestin, and clathrin in JCPyV internalization. These 
studies provide insight into the mechanism of non-enveloped viral entry, which can serve 
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as a platform for the development of potential therapeutic targets for not only JCPyV and 
viral-associated PML, but also for other important human viral pathogens. 
 
Progressive multifocal leukoencephalopathy  
Polyomaviruses are non-enveloped double-stranded (ds) DNA viruses that infect a broad 
range of hosts in nature (3). JCPyV, a human-specific polyomavirus, is considered a 
ubiquitous pathogen because 50-60% of healthy adults are seropositive (3). There are two 
common strains of the virus found in humans: the archetype, non-pathogenic strain that   
can be isolated from the kidney and the PML-type, pathogenic strain that can be isolated 
from the brain of PML patients. During an asymptomatic kidney infection, the virus can 
undergo periods of reactivation and can be shed in the urine. Furthermore, JCPyV has 
been detected in untreated wastewater, suggesting that it is contracted through an oral 
route (1). JCPyV establishes a lifelong, persistent infection in the kidney and B cells of 
bone marrow (4). The majority of infected patients are asymptomatic due to an effective 
immune response to the infection in the kidney. However, JCPyV can undergo 
reactivation when seropositive adults become severely immunosuppressed and the virus 
spreads from sites of persistence to secondary sites of infection, including the CNS. In the 
CNS, JCPyV infects glial cells, astrocytes and oligodendrocytes, and causes cytolytic 
destruction of critical myelin-producing oligodendrocytes, which ultimately leads to PML 
(5).  
PML is diagnosed in a clinical setting through a cranial MRI (Fig. 1) 
demonstrating characteristic white matter lesions in the subcortical area of the brain with 
no mass effect, which indicates the absence of tumors (6). The characteristic white 
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lesions observed on an MRI (Fig. 1) 
indicate areas of myelin loss. A second 
routine method for confirming PML 
diagnosis is the presence of JCPyV 
DNA in the cerebrospinal fluid (CSF) 
through polymerase chain reaction 
(PCR) (6). Most clinicians consider the 
presence of white matter lesions on the 
MRI and the presence of JCPyV DNA in the CSF to be sufficient to diagnose the patient 
with PML (6). These two methods alleviate the need for a much riskier and more invasive 
method of determination, such as a brain biopsy. 
There are several specific populations that are at risk of developing PML (7), with 
the two largest being those infected with the human immunodeficiency virus (HIV-1+) 
and those with multiple sclerosis (MS) who are taking natalizumab as an 
immunosuppressive treatment (7). Additionally, there are distinctions between these 
populations regarding how individuals become immunosuppressed (i.e., a virus or an 
immunomodulatory therapy). Patients who are immunosuppressed by HIV-1 infection 
tend to have PML symptoms associated with weakness, speech abnormalities, and gait 
abnormalities (8). By contrast, those who have natalizumab-induced PML tend to suffer 
from cognitive disorders, motor abnormalities, and visual defects (8).  It has been 
suggested that this could be due to the fact that the lesions of natalizumab-induced PML 
patients are primarily monofocal and develop in the frontal lobe (8). In comparison, HIV-
 
Figure 1: PML lesions and spread.  
Magnetic resonance image (MRI) of development 
of PML lesions over a two-month period. Red 
arrows indicate areas of brain lesion (9). Used 
with permission from ASM. 
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1 induced PML lesions tend to be multifocal, meaning they are in multiple lobes of the 
brain (8). 
The most at-risk population is the HIV-1+ population, which constitutes 
approximately 80% of annual PML cases (7). Unfortunately, there are no effective 
clinical treatments for PML. The only partially effective course of action is immune 
constitution. In HIV-1+ patients, the immune system is deficient and the pathogenic 
strain of JCPyV is capable of spreading to the brain (7). Currently, the common treatment 
for HIV-1 is highly active antiretroviral therapy (HAART). HAART is a combination of 
anti-viral drugs that treat the HIV-1 infection and restore the immune system function in 
patients who are immunosuppressed. Before the development of HAART, PML occurred 
in 3-7% of all HIV-1 cases, accounted for 18% of all fatal HIV-related CNS infections, 
and had a 95% mortality rate (9, 10). Since the development of HAART, the mortality 
rate has fallen from 95% to 30% within one year of symptom onset and down to 60% 
within two years of symptom onset in HIV-1+ patients (7). The incidence of PML has 
also substantially decreased since the introduction of HAART. In a yearly representation, 
the incidence of PML in HIV-1+ patients has decreased over time, from 14.8 cases per 
1,000 in 1996 to 2.6 cases per 1,000 in 2005, and further, to 0.8 cases per 1,000 in 2011 
(11). 
The second largest population at-risk for PML are patients who are receiving 
immunomodulatory therapies for immune-related diseases. The highest incidence of PML 
in this population is among individuals with MS under treatment with the drug 
natalizumab (11). This drug is a humanized monoclonal antibody that blocks autoreactive 
T cells from trafficking to the brain and attacking myelin, a process that constitutes the 
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underlying etiology of MS (7). However, the lack of T cells trafficking to the brain 
results in decreased immune surveillance and is suggested to result in JCPyV reactivation 
in the kidney and spread to the CNS, causing PML (8,9,11). Since 2005, there have been 
over 711 reported cases of PML development in patients receiving natalizumab treatment 
(7). For patients who developed PML from natalizumab treatment, the recommended 
treatment is to stop taking the medication in an effort to reconstitute the immune system. 
However, removal of the therapy can cause PML-immune reconstitution inflammatory 
syndrome (PML-IRIS), an overwhelming inflammatory response that can result in 
neurological worsening, long-term debilitation, and is often in itself, fatal (11). 
Immunomodulatory drugs with life-threatening risks like PML are required by the FDA 
to include a “black box warning” in the prescribing information (12). Natalizumab has a 
black box warning but is regularly prescribed for MS. Even new drugs that have recently 
come to market that have had no incidence of PML development during the extensive 
FDA trial programs, still list PML in a black box warning to inform the consumer that 
there is a chance of life-threatening side effects. 
 
JCPyV attachment and entry 
The first step in the infectious life cycle of viruses is attachment to cell surface receptors 
and subsequent entry into host cells (13). The majority of polyomaviruses studied to date 
use a sialic acid receptor to bind to the surface of target cells (13). JCPyV binds to host 
cells via interactions of the outer capsid protein, viral protein 1 (VP1) with the α2,6-
linked glycan, lactoseries tetrasaccharide c (LSTc) receptor motif (13). There is some 
evidence that JCPyV uses a clathrin-mediated endocytotic pathway that involves cell 
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surface serotonin hydroxytryptamine (5-HT)2 family of receptors (14,25,27). Following 
endocytosis presumably into a clathrin-coated pit, then trafficking to an endosome, the 
enclosed vesicle traffics through the endocytic compartment to the endoplasmic reticulum 
where partial uncoating occurs through the endoplasmic-reticulum-associated protein 
degradation pathway (ERAD) (15). The partially uncoated virion subsequently traffics to 
the nucleus where the virus is completely uncoated and the double stranded DNA 
genome can be transcribed and replicated. JCPyV has temporal gene regulation; 
expression of early gene T-antigen (T-Ag) drives genome replication and the production 
of the late capsid structural viral 
proteins 1, 2, and 3 (VP1, VP2, 
VP3) (15). Following replication, 
the capsid is assembled around 
newly replicated genomes and 
virions are packaged and released 
from the cell.  
 All subtypes of the 5-HT2 
serotonin receptor family; 5-HT2A, 
5-HT2B, and 5-HT2C, rescue JCPyV 
infection in non-permissive cells 
and enhance entry into cells, but the 
mechanism by which this occurs remains unclear (4, 17). Previous studies have suggested 
that JCPyV does not interact with the extracellular loops of 5-HT2Rs on the cell surface 
((13,14) and Atwood Lab, unpublished results)). Thus, the 5-HT2 serotonin receptors play 
 
Figure 2: JCPyV lifecycle. Attachment to host cells is 
mediated through the viral capsid protein, VP1, which 
interacts with the cell surface sialic acid receptor, LSTc. 
After attachment, the virus is thought to be internalized 
through interaction with the serotonin receptors 5-HT2Rs 
via clathrin-mediated endocytosis. Clathrin-coated pits 
can fuse with the early endosomes and transport the virus 
to a caveolin-1+ vesicle and then to the ER. JCPyV is 
partially uncoated in the ER before trafficking to the 
nucleus where transcription, replication, and viral 
assembly occurs. Mature virions are released from the cell 
through cell lysis (1). Used with permission from ASM. 
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a critical role in JCPyV entry, yet the specific mechanism by which these receptors 
facilitate viral entry remains unclear.  
 
Serotonin receptors 
Serotonin receptors of the 5-HT2 subfamily are important neurotransmitter receptors in 
the brain, nervous system, and peripheral tissues (16). The 5- HT2 receptors are seven 
transmembrane-spanning G protein coupled receptors (GPCRs) with three extracellular 
loops and three intracellular loops. 
The intracellular loops contain 
specific binding domains for G 
proteins and other scaffolding 
proteins that when bound activate 
cellular endocytosis and signaling 
(16). After activation by ligands, 
5-HT2Rs can activate two distinct 
signaling pathways, a G-protein 
coupled mechanism, and a b-
arrestin mediated signaling 
pathway, both of which converge 
on the activation of the mitogen-
activate protein kinase pathway (MAPK) (Fig. 3). Additionally, desensitization of the 
receptor and subsequent G-protein uncoupling also activates calmodulin; the reaction 
cascade causes a calcium flux from the ER and further binding and stabilization of 
Figure 3: 5-HT2Rs activation and signaling. Following 
the activation of the receptor, classical GPCR signaling is 
associated with calmodulin recruitment. b-arrestin 
recruitment causes uncoupling of the G protein through 
desensitization of the receptor. The uncoupling event leads 
to clathrin-mediated endocytosis. Clathrin-mediated 
endocytosis requires the scaffolding proteins clathrin, 
AP2, AP180, dynamin, and b-arrestin. This internalization 
is associated with calmodulin-receptor signaling cascades 
that promote the MAPK-ERK cascade, which results in an 
increase in activation and nuclear transcription factors 
(19). Image courtesy of Dr. Melissa Maginnis. 
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calmodulin to the serotonin receptor (18). This activation allows calmodulin to also 
activate the MAPK pathway to stimulate downstream signaling (16) with the MAPK 
pathway acting as a kinase cascade that results in the activation of extracellular signal 
regulated-kinases (ERK), a transcription factor known to be crucial for JCPyV infection 
(1). 5-HT2 receptor antagonists are utilized in the treatment of neurological disorders, 
including mood disorders like depression, (18) and thus serve as a potential target as a 
JCPyV and PML therapeutic. However, it is essential to first understand the exact 
mechanism by which JCPyV is utilizing the 5-HT2Rs to determine which drugs can be 
put forward in testing based on their exact target. 
Previous research has demonstrated that the 5-HT2A, 5-HT2B, and 5-HT2C receptors 
are crucial to JCPyV infection (4). These receptors only have a 50% sequence identity, 
but have key intracellular motifs that are conserved throughout (4). The 5-HT2AR 
contains two calmodulin (CaM)-binding domains, referred to herein as domain 1 and 
domain 2. CaM is a ubiquitous calcium (Ca2+) binding protein sensor, as it is activated 
and regulated by Ca2+ binding. CaM has four Ca2+ binding sites. Ca2+ binding causes a 
conformational change that 
activates CaM to serve as a 
secondary messenger. Once 
activated, CaM can bind to 
specific sites on the serotonin 5-
HT2 receptors (14). The 5-HT2A receptor contains four intracellular motifs that are 
important to clathrin-mediated endocytosis. The (Ala-Ser-Lys) ASK and (Asn-Pro-any 
amino acid (X)-X-Try) NPXXY domains serve as two potential binding sites for the 
Figure 4: 5-HT2Rs conserved intracellular motifs. Key 
intracellular proteins that bind these motifs are highlighted: 
calmodulin binds CaM motifs, b-arrestin binds ASK motifs, 
and clathrin binds NPXXY motifs. 
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CME associated protein, b-arrestin (17). The two CaM-binding sites in the intracellular 
loops of the receptor consist of a 1-8-14 motif (domain 1) and a 1-10 motif (domain 2) 
with hydrophobic residues and potential CaM binding sites at positions 1, 8, 10, and 14 
(14) (Fig. 4). These motifs undergo a conformational change when bound by CaM that 
stabilizes the receptor on the cell surface to allow for interaction with ligands via 
receptor-mediated endocytosis, thus activating signaling events (16,17,18). Therefore, it 
is expected that the presence of serotonin receptors on the surface of the cell is key to the 
internalization and subsequent infection by JCPyV. 
The b-arrestin ligand signaling pathway is activated by viral attachment to the cell 
and causes the uncoupling of the G-protein from the serotonin receptor (17). The 
uncoupling event is thought to be facilitated by the binding of calmodulin and the 
activation of b-arrestin (19). The activation of b-arrestin facilitates the internalization of 
the 5-HT2A receptor via clathrin-mediated endocytosis. Clathrin-mediated endocytosis 
requires the recruitment of endocytic scaffolding proteins, such as AP2 and clathrin. In 
turn, these proteins stimulate downstream signaling cascades that promote the activation 
of cellular transcription (Fig. 2). Preliminary data from the Maginnis Laboratory has 
shown that b-arrestin and the MAPK pathway are crucial for JCPyV infection. 
Understanding how JCPyV is able to tip the activation of the serotonin receptor away 
from the G-protein coupled signaling and towards the b-arrestin mechanism is essential 
to understanding how drugs could be used to target 5-HT2Rs signaling pathways and 
serve as effective therapeutics. 
In an attempt to treat PML, clinicians have prescribed chemical antagonists that 
target the reuptake of serotonin, such as selective serotonin reuptake inhibitors (SSRIs) in 
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off-label treatment regimens. Several studies have assessed the use of different drugs that 
target serotonin receptors in open label or anecdotal PML studies. One serotonin 
antagonist that has been tested is the antidepressant mirtazapine. Mirtazapine has been 
shown to selectively inhibit 5-HT2 and 5-HT3 receptors (20) and block JCPyV infection 
in human glial cells (21). Reports of these anecdotal trials demonstrate that mirtazapine 
treatment has varying degrees of efficacy in PML patients. There is evidence that 
mirtazapine can improve the prognosis of patients who are diagnosed with PML. Indeed, 
many studies have shown a significant decrease in the neurological deterioration and 
detectable viral loads in the blood and CSF (22). On the other hand, reports have yielded 
results that suggest mirtazapine is largely ineffective. In these studies, patients’ 
conditions rapidly deteriorated despite being treated with the 5-HT2R antagonist, and 
there were no remarkable MRI changes in the infected patients (23). Thus, it is 
questionable whether or not mirtazapine alone is an effective treatment of PML, but 
studies have shown that it can be more effective when used with an anti-parasitic drug, 
mefloquine, which has been shown to decrease JCPyV replication in vitro 
(7). Mefloquine, a treatment for malaria, has been shown to be effective in treating 
individuals with PML by causing a decreased JCPyV infection after the virus has entered 
the cell (24,25,26). Taken together, these results suggest that mirtazapine may be 
efficacious in preventing cell-to-cell spread of JCPyV by blocking infection of new cells 
while mefloquine may be capable of treating underlying JCPyV infection where infection 
has already been established. While the reports for use of mirtazapine and mefloquine are 
promising, the conflicting evidence between these reports suggests that further 
investigation and exploration is needed in determining the method of JCPyV-mediated 
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infection by 5-HT2Rs. There should also be continued exploration of off-label use of 
approved therapies in the treatment of JCPyV and PML.                                                                               
                     
Clathrin-mediated endocytosis 
JCPyV is a non-enveloped virus; it must traverse the host cell membrane in order to 
establish infection and is unable to fuse with the membrane like enveloped viruses (27). 
Therefore, the virus must be internalized via a cellular endocytic pathway such as 
clathrin-mediated endocytosis, micropinocytosis, or caveolin-dependent endocytosis (27). 
It is proposed that JCPyV uses clathrin-mediated endocytosis for viral entry because 
chemical inhibitors of clathrin-mediated endocytosis, including chlorpromazine, limit JC 
virus infection (27). However, the mechanism by which this occurs is not well 
understood because chlorpromazine has been shown to act as an antagonist of serotonin 
receptors (25). CME is a process that is inherent to all cells as a method of internalizing 
host factors that are needed for homeostasis and proliferation. Further, it is unknown 
whether JCPyV-mediated CME occurs through direct virus-host interactions with the 5-
HT2 receptors. Previous literature has shown that JCPyV infection of host glial cells 
requires the internalization of the CME associated protein, epidermal growth factor 15, 
eps15 (27). There is additional evidence that that dominant-negative eps15 mutants 
inhibit clathrin-dependent endocytosis (27). The dominant negative mutants also caused a 
decrease in JCPyV internalization, further demonstrating that JCPyV likely enters the cell 
in a clathrin-mediated fashion. This method of entry is different than its most closely 
related polyomavirus, SV40. Even though they are very similar, SV40 uses sialic-acid-
containing ganglioside receptors and enters via a non-clathrin mediated mechanism (27). 
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 Clathrin-mediated endocytosis is a complex and diverse cellular entry pathway 
and has been chiefly reported to require cellular scaffolding proteins AP2, AP180, and 
clathrin. However, activation of proteins involved for internalization is ligand-specific 
and may vary based on the receptor utilized in addition to receptor-ligand activation. 
Both AP2 and AP180 are able to bind to b-arrestin and recruit clathrin to the cell surface 
(26). The classical view is that CME is initiated by the recruitment of AP2 to the plasma 
membrane of the cell (28) and acts in conjunction with AP180 to attract clathrin for the 
invagination of the receptor and virus (Fig. 5). This view is supported by research that 
found that the mutation 
of AP2 binding sites in 
the eps15 protein 
significantly decreased 
the infection of a virus 
that uses CME (29). It 
has been shown that 
the use of siRNA 
against the µ2 subunit of AP2 showed a significant decrease in the formation of clathrin 
coated pits and vesicles, as the µ2 subunit contains a conserved motif capable of 
interacting with GPCRs and facilitating CME pit formation (28). This indicates that AP2 
is an important scaffolding protein capable of interacting with b-arrestin and can limit 
CME, but it is not the only scaffolding protein that is crucial for CME. 
 AP180 is thought to act in a combinatorial manner with AP2 in clathrin 
recruitment to the membrane of cells, yet the mechanism is not well understood (30). 
Figure 5: Clathrin-mediated endocytosis. Ligand binding to receptors 
leads to recruitment of AP2 and clathrin to the plasma membrane 
(Binding/Recruitment). Membrane curvature forms a pit inside the cell 
(Invagination/Maturation). Scission by dynamin causes internalization 
of cargo in a clathrin-coated vesicle (36)) Used by permission from 
MBInfo. 
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Studies have demonstrated that AP2 and AP180 colocalize and potentiate the binding of 
clathrin to clathrin-coated vesicles (30) There is additional evidence that AP180 is four 
times more efficient and effective at recruiting and binding to clathrin (28). Even though 
AP180 is four times more effective at binding to clathrin, it has been shown that AP2 and 
AP180 work together and are most effective when colocalized on the clathrin-coated 
vesicle (30). Similar to AP2, the reduction of one protein does not completely abolish the 
presence of clathrin-coated vesicles, likely indicating that the APs are capable of 
recruiting clathrin in the absence of the other. 
 The most important protein for CME is clathrin itself. Upon recruitment of AP2 
and AP180 to the plasma membrane, clathrin is recruited to the membrane to serve as an 
outside coat for the vesicle (29). Interestingly, clathrin does not directly interact with the 
invaginating membrane or the activated receptor, but has direct interactions with 
scaffolding machinery around the pit. Once the vesicle is internalized into the cell, the 
clathrin coat detaches and the contents of the vesicle become accessible to the cellular 
endocytic pathway. It has been shown that the abolishment of the heavy chain of clathrin 
causes a significant reduction in the presence of clathrin-coated vesicles in cells (30). 
This finding demonstrates that clathrin is crucial for clathrin-mediated endocytosis. If 
JCPyV requires clathrin-mediated endocytosis for infectious entry, then the abolishment 
of any of these proteins in vitro will likely impact infection. 
 
Research goals 
The research discussed in this thesis explores the role of CME-scaffolding proteins and 5-
HT2R-protein interaction domains in JCPyV infection of human glial cells, resulting in 
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JCPyV entry limitation by the abolishment of the clathrin-mediated scaffolding proteins 
AP2, AP180, and b-arrestin, but not by the limitation of calmodulin. Entry was further 
prevented by degrading clathrin, the key protein involved clathrin-mediated endocytosis. 
These studies were conducted to further build on published literature and unpublished 
work in the Maginnis Laboratory, which demonstrate that JCPyV is internalized into its 
human host cells through clathrin-mediated endocytosis. This information will contribute 
to the broader understanding of non-enveloped viral entry through clathrin-mediated 
endocytosis. In addition, this research will provide new information about JCPyV entry 
and possible mechanisms that can be targeted in the development of new antiviral 
therapies. 
 
Materials and Methods 
Cell culture maintenance 
A Lab Gard II laminar flow hood was used to limit contamination while conducting cell 
culture experiments. SVG-A and HEK293A (Human Embryonic Kidney) cell lines were 
used and cultured in T75 flasks that were grown in a humidified incubator at 37°C with 
5% CO2. Both lines were passaged upon viewing approximately 90% confluence under 
an inverted microscope. The SVG-A cell line was cultured in Minimum Essential 
Medium (MEM) supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin (P/S) (Mediatech, Inc.), and 0.2% plasmocin (Invivogen). 
HEK293A cells were cultured in similar conditions, except Dulbecco’s Modified Eagle 
Medium (DMEM) were used in place of MEM. Both lines are adherent and were 
detached by a 5-minute incubation at 37ºC with 4ML of 0.5% trypsin-EDTA (Gibco by 
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Thermo Fischer Scientific). Following incubation, 9mL of fresh media was added to the 
flask. The media, now containing the detached cell line was transferred to a 15mL conical 
tube. The tube was centrifuged at 2,000 rpm for 5 mins. Pelleted cells were resuspended 
in fresh complete growth media and divided to a new flask based on the desired growth 
period. The new flask was then cultured in a humidified incubator at 37ºC and 5% 
humidity until reaching confluence; at that time the process was repeated. 
 
JCPyV and SV40 infection 
Cells were treated with a chemical inhibitor or transfected with siRNA, before media was 
removed and the cells were infected with JCPyV or SV40 (MOIs indicated in Figure 
Legends). Viral infection was conducted in MEM with 2% FBS and no antibiotics in a 
200µL volume. After a 1-hour incubation at 37ºC, cells were fed with 1mL of complete 
MEM and allowed to incubate at 37ºC for 72 hrs before being fixed and stained by 
indirect immunofluorescence. 
 
Calmodulin inhibition 
Calmidazolium chloride (Santa Cruz Biotechnology) was reconstituted in DMSO and 
used at indicated concentrations. SVG-A cells were plated at 2.5x104 cells per well in a 
24 well plate overnight. Upon 70% confluency, cells were treated with indicated 
concentrations of inhibitor for 3 hrs prior to infection. Cells were immediately infected 
after the pre-treatment with JCPyV (MOI of 1FFU/cell) in MEM containing 2% FBS and 
incubated at 37ºC for 1 hour. After the incubation, cells were fed with 1mL of room 
temperature MEM with 10% FBS and 1% P/S, incubated for 72 hrs at 37ºC, then fixed 
		 	 16	
and stained by indirect immunofluorescence. Infection was quantified by the number of 
VP1 positive nuclei in a visual field. 
  
Indirect immunofluorescence 
Following infection, cells were washed once with 1xPBS then fixed in ice cold methanol. 
Fixed cells were incubated at -20ºC for greater than 10 mins before staining. After 
incubation at -20ºC, cells were washed with 1xPBS 3 times for 10 mins each followed by 
a 15-minute incubation with PBS-0.5% TX100 for permeabilization of the cellular 
membranes. Cells were stained with a primary antibody, PAB597 (1:10) a hybridoma 
supernatant that produces a monoclonal antibody against JCPyV VP1 (33) and was 
generously provided by Ed Harlow. A secondary anti-mouse Alexa Fluor 488 antibody 
(Thermo Fisher Scientific) was used to detect VP1+ cells. Cells were quantified for 
infectivity by fluorescence microscopy by counting VP1+ cells in at least 5 visual fields 
per well in triplicate wells for 3 separate experiments. Expression of VP1 was observed 
under a 10x objective using a Nikon Eclipse Ti epifluorescence microscope. Percent 
infection was quantified by the number of VP1+ nuclei per visual field divided by the 
number of DAPI positive nuclei in the same field. The number of DAPI positive cells 
were quantified using a binary created in the Nikon NIS-Elements Basic Research 
software (Version 4.5), controlling for equal diameter and circularity of DAPI-stained 
nuclei based upon threshold fluorescence. The average percentage of infected cells was 
then normalized to the EGFR control siRNA. Significance was determined using a 
Students’ t-test (Microsoft Excel). 
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Flow cytometry to measure serotonin receptor expression 
HEK293A cells were transfected with mutated 5-HT2A serotonin receptors in a 6 well 
plate (0.5e6 cells per well) and allowed to grow overnight to 100% confluence. Media 
was aspirated from the wells and all of the wells were washed with 1xPBS. The cells 
were then incubated in Cellstripper (Corning). Cells were pooled in 1.5mL 
microcentrifuge tubes, pelleted at 2500 rpm for 5 mins at 4ºC, and washed with PBS. 
Cells were incubated with a 1:250 dilution of the 5-HT2A receptor primary antibody, SR-
2A (Santa Cruz Biotechnology), for 30 mins at 4ºC. After the incubation, the cells were 
pelleted at 2500 rpm for 5 mins and washed 3 times with PBS. A total of 100µL of the 
cells were transferred to a new tube and were incubated with the secondary antibody, 
anti-rabbit Alex Fluor 488 antibody (Thermo Fisher Scientific). Incubation was 
conducted on ice for 2 hrs with agitation of the solution every 15 mins. Cells were 
washed, pelleted by centrifugation at 2500 rpm, and resuspended in 500µL of PBS. Cells 
were analyzed for 5-HT2A receptor expression of the cell surface using a BD FACSCanto 
(BD Biosciences) equipped with a 488 laser excitation line (Benton, Dickinson, and 
Company). The data generated by this experiment were analyzed using BD FacsDIVA 
(Benton, Dickinson, and Company) and FlowJo software (Tree Star, Inc.). 
 
Mutation of serotonin receptors 
Calmodulin binding domains in the 5-HT2A receptor were mutated using a Qiagen site-
directed mutagenesis kit. All of the sites (F186, V193, F199, L382, and F391) were 
mutated to alanine residues. Mutagenesis was previously performed by Dr. Melissa 
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Maginnis. Following the transformation, plasmids were amplified and isolated using a 
Qiagen Maxi Prep kit.  
 
Transfection of mutated receptors 
HEK293A cells were plated to 80% confluence in a 24 well plate at the time of 
transfection. Before addition to the wells, 0.5µg/well of the receptor plasmids were mixed 
in incomplete medium lacking serum or antibiotics. In a separate tube, 1µL/well of 
Lipofectamine 2000 (L2000) (Thermo Fisher Scientific) was mixed with incomplete 
medium lacking serum or antibiotics (Invitrogen). Plasmids and L2000 were incubated in 
their respective tubes for 5 mins then before combined. Combined samples were mixed 
well and incubated at room temperature for 15 mins. After incubation, 100µL were added 
per well in a dropwise fashion and allowed to incubate in a humidified, 37ºC incubator 
for 4 hrs. Following the incubation, the media was removed and 1mL of complete media 
containing serum and antibiotics was added to cells. Transfection of plasmids was 
allowed to progress for 24 hours before experimental use. 
 
siRNA treatment 
SVG-A cells were plated to approximately 50% confluence in 10% FBS MEM without 
antibiotics in a 12 well plate. Cells were then allowed to adhere for 4 hrs before 
transfection with siRNAs specific for AP2 (Dharmacon), b-arrestin (Cell Signaling 
Technology), AP180 (ThermoFischer), clathrin heavy chain (Life technologies), 
unconjugated non targeting control (Cell signaling technology 65685), or an EGF 
receptor control (Cell Signaling Technology 64825). b-arrestin, clathrin heavy chain, 
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AP180, and AP2 siRNA (30 or 60 pmol) was complexed with RNAiMax transfection 
reagent (Invitrogen) in serum- and antibiotic-free MEM (Corning) and incubated at room 
temperature (RT) for 10 mins. Transfection mixtures were added to cells incubated in 
1mL of serum- and antibiotic-free MEM dropwise. Transfections were performed as 
follows: b-arrestin siRNA: 30pmol for 72hrs; clathrin heavy chain siRNA: 30pmol for 
24hrs, then washed in MEM and transfected with 30pmol for 48hrs; AP2 and AP180 
siRNA (single or double transfections): 30pmol for 72hrs or 30pmol for 48hrs, then 
washed in MEM and transfected with 30pmol for 24hrs for double transfection samples. 
All siRNA transfections were allowed to proceed for 72hrs total prior to infection. 
Transfection efficiency was monitored using Block-iT Alexa Fluor Red Control Oligo 
(Life Technologies) visualized at 48 hrs post transfection by fluorescence microscopy.  
Complexes were added to each well in 100µL volumes in a dropwise fashion and 
incubated at 37ºC for 72 hrs; the transfection medium was not removed. At 72 hrs post-
transfection, cells were infected with JCPyV or SV40 in MEM with 2% FBS and 
incubated at 37ºC for 1 hour. Cells were fed with 1mL of complete MEM containing 
antibiotics, incubated for 72 hrs, then fixed with 100% ice cold methanol and stained by 
indirect immunofluorescence. The percentage of infected cells was quantified as 
described previously. 
 
siRNA western blot analysis 
In order to analyze protein knockdown following siRNA treatment, SVG-A cells were 
washed with PBS after a 72-hour treatment of the AP2 siRNA. Cells were scraped from 
the wells and pelleted by centrifugation at 2500 rpm at 4ºC for 5min. Pellets were 
		 	 20	
resuspended in 50µL of Tris-HCl lysis buffer that contained both protease (1:10) and 
phosphate (1:100) inhibitors. Samples were incubated on ice for 10 mins before 
centrifugation at 18,600 rpm at 4ºC for 10 mins. The supernatants were transferred to a 
new tube and were mixed (1:1) with 2X Laemmli sample buffer containing  
b-mercaptoethanol. Samples were resolved on a 10% SDS-PAGE TGX gel (BioRad) that 
was run at 9 milliamps in a Bio-rad Mini gel box. Proteins were transferred to a 
nitrocellulose membrane using the rapid blot transfer program on the Trans-Blot Turbo 
Transfer System (BioRad). Membranes were blocked using 5% non-fat dry milk with 
0.1% TBS-T overnight. Blots were then washed three times at RT for 10 mins with TBS-
T (0.1% Tween) while vigorously rocking. Following washing, the blot was incubated 
overnight while rocking at 4ºC with an antibody specific for AP2 (1:1000) (Cell 
Signaling Technology) and polyclonal antibody for GAPDH (loading control) (1:2000) 
(Abcam) in 5% BSA/ 0.1% TBS-T. Membranes were washed in TBS-T at RT, then 
incubated with a secondary antibody at 1:15,000 (LICOR) dilution at RT for 1 hour in 
5% milk with TBS-T. Membranes were washed in TBS-T and TBS, then imaged using a 
LICOR Odyssey Clx. Results were quantified using the Image Studio program (LICOR). 
 
Results 
Clathrin inhibition decreases JCPyV infection  
Previous studies have shown that chemical inhibition of the clathrin-mediated 
endocytotic pathway reduces JCPyV infection (4,34). To further determine whether 
clathrin-mediated endocytosis is crucial to infection, key proteins, including clathrin, 
were targeted through siRNA treatment. SVG-A cells were transfected with a siRNA 
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targeted toward clathrin heavy chain to 
reduce clathrin protein levels in cells 
(Fig. 6). Cells were then infected with 
JCPyV and infection was quantitated by 
indirect immunofluorescence in a viral 
fluorescent focus unit (FFU) assay. 
Cells expressing a clathrin siRNA 
demonstrated an approximately 80% 
decrease in infection in comparison to 
cells treated with a control siRNA (Fig. 
6). These data suggest that clathrin is 
crucial for JCPyV infection.  
 
The role of calmodulin in JCPyV infection is inconclusive  
We hypothesized that the 
interaction of calmodulin with the 
5-HT2R plays a crucial role in 
JCPyV infection. To investigate the 
role of calmodulin in JCPyV 
infection, SVG-A cells were 
treated with a calmodulin 
antagonist, calmidazolium 
chloride, infected with JCPyV, and 
 
 
Figure 6: Clathrin heavy chain siRNA limits 
JCPyV infection. SVG-A cells were pretreated 
with an siRNA specific to clathrin heavy chain 
(CHC) or a control protein (EGFR). The cells were 
then incubated for 72 hrs. Following this 
incubation, cells were infected with JCPyV (MOI of 
0.1FFU/cell). Infection was quantified by indirect 
immunofluorescence using a VP1-specific antibody 
at 72 hrs post infection. Data represent the average 
percent infection for 5 fields of view for triplicate 
samples; CHC siRNA in comparison to an siRNA 
control. *,P <0.01 denotes significance determined 
by students’ t-test. 
 
 
Figure 7: Calmidazolium chloride limits JCPyV 
infection. SVG-A cells at 90% confluency were pretreated 
for 3 hours with a calmodulin antagonist at the 
concentrations indicated. After treatment, cells were 
infected for 72 hours with JCPyV (MOI of 1FFU/cells). 
Cells were quantified by indirect immunofluorescence. Data 
represent the average number of infected cells in a 10X field 
for 5 visual fields. *, P <0.05 denotes significance 
determined by students’ t test. 
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infection was scored using an FFU assay. Cells treated with calmidazolium chloride led 
to a significant decrease in infection at concentrations at or above 0.75-1µM (Fig. 7). 
However, treating cells with concentrations greater than 1µM of calmidazolium chloride 
did not result in a dose-dependent decrease in infection. This suggests that the antagonist 
may have a secondary effect that is limiting infection, or the maximal efficacious 
inhibitor concentration was reached without compromising cellular viability. An MTS 
assay was performed to view cellular viability. There was a significant decrease in 
cellular proliferation between a 0.75µM and 1µM treatment of calmidazolium chloride 
(data not shown).   
 To further investigate the role of calmodulin, and to define direct calmodulin-
receptor interactions, serotonin receptors with specific calmodulin binding domain 
mutations were generated. Each of the key amino acids in the 1-8-14 and 1-10 motif of 
Figure 8: 5-HT2A receptor cell surface expression. HEK293A cells were transfected with the 
transfection reagent (L2000) and the wild-type and mutant 5-HT
2A
Rs for 24 hours. After transfection, 
the cells were stained with a 5-HT
2A
 specific antibody and complementary secondary fluorescent 
antibody. Fluorescence was quantified by flow cytometry. Histograms represent the median 
fluorescence intensity for 10,000 events.  
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the 5-HT2A receptor, F186, F199, V193, L382, and F391, were mutated to alanine. The 
serotonin receptors with mutated CaM-binding domains were transfected into HEK293A, 
a poorly permissive cell line. Previous research by the Maginnis Lab has shown that 
when the mutated receptors were transfected into HEK293A cells then infected with 
JCPyV there was a significant decrease in infection in the F391A mutant receptor yet no 
difference in infection was observed for other mutations tested (Maginnis Lab, 
unpublished data). To determine if this decrease was due to a lack of calmodulin binding 
or a decrease in the ability of the receptor to be expressed on the cell surface, the cell 
surface expression of the mutated receptors was analyzed. HEK293A cells were 
transfected with the wild-type and mutant 5-HT2A receptors and stained with a serotonin-
specific antibody and complementary secondary fluorescent antibody, and cell surface 
expression of the receptor was determined by flow cytometry. All of the mutated 
receptors were expressed on the cell surface at levels greater than the vehicle control 
(L2000) but at levels that were lower than the wild type 5-HT2A receptor (Fig. 8). The 
mutated receptor had reduced cell-surface expression in comparison to the wild-type 5-
HT2A receptor, and (F391A) was the only receptor that had a decreased infection (Fig. 8. 
and Maginnis Lab, unpublished data). Thus, the decrease in infection in cells expressing 
the F391A mutant could be due to reduced surface expression of the receptor. Taken 
together, these data are not sufficient to determine whether calmodulin is crucial to 
JCPyV infection, and the role of other scaffolding proteins involved in CME were further 
explored.  
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siRNA targeting of b-arrestin, AP2, and AP180 significantly decreases JCPyV 
infection  
b-arrestin binds to the 5-HT2R b-arrestin domain, then scaffolds and recruits AP2, 
AP180, and clathrin (18). It also plays an important role in the uncoupling of G proteins 
from serotonin receptors (18). This 
data suggests that b-arrestin may play 
a crucial role in JCPyV entry in a 
clathrin-mediated endocytic manner. 
To explore this further, SVG-A cells 
were transfected with a siRNA 
specific to b-arrestin and infected 
with JCPyV or SV40 polyomavirus 
as a control (Fig. 9). Cells treated 
with the b-arrestin siRNA 
demonstrated an 80% decrease in 
JCPyV infection compared to cells expressing a control siRNA, while no significant 
reduction was noted in the SV40 infection (Fig. 9). These data suggest that b-arrestin is 
crucial to JCPyV infection and that JCPyV enters host cells in a clathrin-mediated 
pathway that is distinct from the SV40 endocytotic pathway.  
To further demonstrate that JCPyV uses clathrin-mediated endocytosis, an AP2-
specific siRNA was used to reduce AP2 expression. Cells were transfected with the AP2 
siRNA, followed by infection with JCPyV or SV40 (Fig. 10A), resulting in a ~70% 
decrease in JCPyV infection in cells treated with an AP2 siRNA compared to cells treated 
 
 
Figure 9: β-arrestin limits JCPyV infection. SVG-
A cells were pretreated with a siRNA oligo specific 
to clathrin heavy chain (CHC) or control (EGFR). 
The cells were then incubated for 72 hrs. Following 
this incubation, cells were infected with JCPyV or 
SV40 (MOI of 0.1 or 0.0001FFU/cell respectively) 
for 72 hrs. Data represent the average percentage of 
infected cells per visual field for five visual fields for 
β-arrestin siRNA in comparison to a siRNA control. 
*, P <0.01 denotes significance determined by 
students’ t test. 
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with a control siRNA (Fig. 10A). Comparatively, SV40 infection was not impacted in 
cells that were treated with an AP2-specific siRNA or a control siRNA. These data 
suggest that AP2 is also crucial for JCPyV infection.  
 To confirm that the AP2 siRNA was specifically reducing the levels of AP2 
protein in the cell, a western blot was performed (Fig. 10B). SVG-A cells were treated 
with an AP2-specific siRNA or a control siRNA and cell lysates were resolved by SDS-
PAGE and analyzed by western blot using an antibody specific to AP2 or a control 
GAPDH and complementary secondary antibodies. Protein levels were quantified using a 
LiCOR Odyssey Clx, and there was a 75% decrease in AP2 protein in the cells treated 
with the AP2 siRNA compared to cells treated with the control siRNA (Fig. 10B). This 
data suggests that the siRNA for AP2 is working properly and degrading the AP2 protein.  
A      B 
  
Figure 10: AP2 degraded by siRNA significantly impacts JCPyV infection. (A) SVG-A cells were 
pretreated with a siRNA oligo specific to AP2 or control (EGFR). The cells were then incubated for 72 
hrs. Following this incubation, cells were infected with either JCPyV or SV40 (MOI of 0.1 and .000l 
FFU/cell respectively) and infection was allowed to progress for 72 hrs. Data represent the average 
percentage of infected cells per visual field for five visual fields for AP2 siRNA in comparison to a siRNA 
control. (B) SVG-A cells were pretreated with an AP2-specific siRNA for 72hrs in a 6 well plate. 
Following incubation, proteins were run on a SDS page gel and stained with a secondary antibody for 
AP2 or GAPDH (control). *, P <0.01 denotes significance determined by students’ t test. 
 
		 	 26	
 To explore the impact of AP180 in an absence or presence of AP2 in JCPyV 
infection, cells were transfected with an AP2 siRNA, AP180 siRNA, or a mixture of both 
siRNAs (Fig. 11). It was observed 
that the AP180 siRNA had a 60% 
decrease in infection and the AP2 
siRNA had a 35% decrease in 
infection when compared to a 
control siRNA (Fig. 11). The dual 
siRNA treatment had the most 
significant effect on infection and 
decreased infection by 80% when 
compared to a control siRNA. 
These results indicate that while 
both adaptor proteins are required for infection, the impact of AP180 is greater than that 
of AP2. Additionally, this further suggests that AP2 and AP180 are crucial to JCPyV 
infection and that AP2 and AP180 may act in a collaborative fashion because an additive 
effect was observed. These data suggest that JCPyV requires AP2 and AP180 for 
successful infection of human glial cells.  
 
Discussion 
JCPyV was previously shown to require the activity of 5-HT2R serotonin 
receptors for viral entry into host cells (4). Furthermore, evidence has demonstrated that 
JCPyV entry occurs in a clathrin-dependent manner (4). However, the evidence that led 
 
Figure 11: Dual AP2 and AP180 siRNA treatment 
limits JCPyV infection. SVG-A cells were treated with an 
siRNA specific for AP2, AP180, or both (AP180 and AP2), 
or control (EGFR) for 72 hrs. Following incubation, cells 
were infected with JCPyV (MOI of 0.1FFU/cell) for 72 
hrs. Infection was quantified as percent infection for the 
AP2-, AP180-, or dual-siRNA treatment in comparison to 
a siRNA control *,P <0.01, denotes significance 
determined by students’ t test.  
 
		 	 27	
to the conclusion that JCPyV enters cells by clathrin-mediated endocytosis is based on 
the finding that chlorpromazine can inhibit JCPyV infection (23). While chlorpromazine 
is widely used in the field of virology to limit clathrin-mediated endocytosis, it is also a 
5-HT2R serotonin receptor antagonist (23) and is thus not an appropriate inhibitor for use 
in JCPyV studies. Therefore, the mechanism of JCPyV entry required further 
investigation using more specific inhibitors and additional methods to determine whether 
clathrin and related scaffolding proteins are essential for JCPyV entry into host cells. 
Herein, I have demonstrated that JCPyV infection is dependent upon clathrin, as 
evidenced by a significant reduction in JCPyV infection in cells treated with an siRNA 
directed toward clathrin heavy chain (Fig. 6). Though calmodulin is thought to play a role 
in uncoupling the classical GPCR G-protein signaling pathway and activating a b-arrestin 
specific endocytic pathway, inhibition of calmodulin by a chemical inhibitor did not have 
a significant effect on JCPyV infection (Fig. 7), indicating that calmodulin may not be 
involved in JCPyV infection and requires further exploration. However, gene silencing of 
b-arrestin, a scaffolding protein that can bind directly to 5-HT2Rs, and other scaffolding 
proteins essential for clathrin-mediated endocytosis including AP2 and AP180, 
significantly prevented viral infection (Fig. 9, 10, and 11), indicating that JCPyV utilizes 
clathrin-mediated endocytosis to infect host cells.  
 Despite previous evidence that calmodulin plays a role in JCPyV infection 
(Maginnis Lab, unpublished results), we found conflicting results that render our data 
inconclusive. We investigated the role of calmodulin in JCPyV infection as it has been 
previously reported that calmodulin binding to the serotonin receptor activates the 
receptor and plays a role in endocytosis and activation of signaling events (18,19). 
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However, treatment of cells with the inhibitor calmidazolium chloride led to a decrease in 
JCPyV infection, yet the reduction in infection was not dose-dependent (Fig. 7). An MTS 
toxicity assay revealed that calmidazolium chloride was toxic to the cells at higher 
concentrations (data not shown). Therefore, the chosen inhibitor was not acting as 
expected and was most likely having secondary effects, or high enough concentrations 
necessary to inhibit calmodulin were not obtainable due to cellular toxicity effects. 
Further, we demonstrated that a decrease in infection could be achieved by mutating the 
phenylalanine at position 391 to an alanine (F391A), but this receptor was shown to have 
reduced cell surface expression by flow cytometry compared to the wild type 5-HT2AR 
receptor (Fig. 8). This indicates that the decrease in infection demonstrated by the F391A 
mutant could be due to a loss of calmodulin interaction or that there are fewer receptors 
on the surface that could be utilized for entry. Taken together, these data are not 
conclusive to determine the role of calmodulin in JCPyV entry. To further define the role 
of calmodulin in JCPyV infection, an additional chemical inhibitor that limits calmodulin 
in the cell should be explored. Additionally, further research should be conducted into the 
residues that interact with calmodulin by making multiple mutations, instead of single 
point mutations in 5-HT2AR. 
 We also demonstrated that JCPyV uses a clathrin mediated-endocytic entry 
pathway as gene silencing of key scaffolding proteins involved in 5-HT2R internalization, 
b-arrestin, AP2, AP180, and clathrin, significantly reduced infection. Interestingly, cells 
that received a double AP2 siRNA treatment (Fig. 10A) had an even greater decrease in 
JCPyV infection and cellular toxicity than those that received a single treatment of AP2 
or AP180 siRNA (Fig. 11). This observed effect could be due to the fact that a double 
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transfection of siRNA against the AP2 µ2 subunit causes the knockdown of the alpha and 
beta appendages that interact with AP180, which has been previously demonstrated in the 
literature (37). This indicates that the significant decrease in a dual siRNA treatment of 
AP2 could be due to the limitation of both AP2 and AP180 rather than just AP2. Taken 
together, these data suggest that JCPyV is utilizing a mechanism for entry similar to that 
of the activated 5-HT2R receptor.  
 The closely related polyomavirus, SV40, was used as a control, and treatment of 
cells with siRNAs specific for b-arrestin, AP2, AP180, and clathrin, had no effect on 
SV40 infection (Fig. 9 and 10. and not shown data.) This confirms that the activation of 
clathrin-mediated endocytosis in SVG-A cells is specific for JCPyV as it differs from a 
close viral relative. This data further aids our understanding of the processes involved in 
JCPyV entry and, more broadly, how viruses are able to enter cells. Future studies will 
focus on defining the role of other 5-HT2R clathrin mediated endocytic proteins in 
JCPyV infection and exploring whether inhibition of these scaffolding proteins plays 
roles in the ability of the virus to bind to host cells. 
 b-arrestin mediated endocytosis has been shown to lead to the activation of 
signaling events, including those in the MAPK pathway. MAPK signaling can then lead 
to the activation of another group of signaling proteins, extracellular–signal regulated 
kinases (ERK). The Maginnis Laboratory has previously demonstrated that ERK is 
crucial to JCPyV infection (Dushane et al., submitted manuscript). Because b-arrestin has 
been implicated as an activator of ERK in other studies, this further suggests that b-
arrestin aids in JCPyV entry in a clathrin-mediated entry process and the activation of 
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scaffolding proteins at the time of entry may be impacting activation of downstream 
signaling cascades crucial for the JCPyV infectious lifecycle. 
 The data presented in this thesis demonstrates the entry mechanism utilized by 
JCPyV in SVG-A cells. 
Based on the reported 
findings, we have generated 
a working model for JCPyV 
entry (Fig. 12). Upon viral 
activation of the 5-HT2R, b-
arrestin binds to the receptor, 
likely causing the uncoupling 
of the G-proteins, which 
leads to receptor desensitization and subsequent internalization. b-arrestin causes further 
recruitment of scaffolding proteins AP2, and AP180, which lead to the recruitment of 
clathrin. AP2 and AP180 have been reported to act in cooperation to recruit and stabilize 
clathrin at the plasma membrane. Collectively, the presence of these proteins within the 
cell are crucial to JCPyV entry into permissive host cells.  
 In recent years, the incidence of PML has increased in the HIV/AIDS population 
and those undergoing immunosuppression therapies for immunological disorders, such as 
multiple sclerosis (8). If left untreated, PML is a rapidly fatal, devastating disease. 
Treatment options for PML are currently ineffective and inadequate, and sometimes lead 
to the patient’s condition worsening (7,8). In order to develop effective therapies, the 
scientific community must first understand the mechanisms of JCPyV entry, as it 
 
Figure 12: Model of JCPyV entry. b-arrestin binding to the 5-
HT2Rs recruits the scaffolding protein AP2 and AP180. AP2 and 
AP180 act to recruit clathrin. Clathrin mediates endocytosis of 
the receptor and JCPyV into the cell. 
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illuminates targets for potential antiviral therapeutics. The present study provides new 
information confirming that JCPyV enters through clathrin-mediated endocytosis and that 
key scaffolding proteins for receptor internalization, b-arrestin, AP2, AP180, and 
clathrin, are also crucial to JCPyV entry.  
 These proteins can serve as new targets for therapeutics to prevent PML.  
Approximately 25% to 30% of drugs on the market utilize GPCRs as a target (35). The 
mechanism of many of these treatments, including the SSRI drugs and GPCR-targeting 
drugs that have been utilized for treatment in PML, is still unknown. The present research 
contributes to efforts to produce efficacious drugs by determining that b-arrestin, AP2, 
AP180, and clathrin are crucial to JCPyV entry, thus providing new targets for potential 
treatments. Indeed, some of the b-blocker class of GPCR-targeting drugs on the market, 
such as Nebivolol, have been shown to specifically target b-arrestin (39). Drugs like 
these give us confidence that understanding the biological basis of viral entry, 
specifically the role of scaffolding proteins like b-arrestin, can optimize treatment 
efficacy. Thus, if we are able to contribute to the design of a new drug that has the 
potential to limit JCPyV entry and subsequent spread of the virus, the incidence of PML 
may be reduced. For example, a b-arrestin- or 5-HT2R-specific drug could be combined 
with mefloquine, an anti-malarial drug that has demonstrated decreased JCPyV infection 
at a post-entry step (24), in a dual therapy paradigm to limit the progression or 
development of PML. This treatment option could not only lead to cognitive 
improvements in patients with PML, but also ultimately reduce the number of cases of 
PML that develop; it has been demonstrated that dual treatments of mefloquine with a 
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serotonin antagonist have, in some cases, reduced PML symptoms and JCPyV presence 
in the CSF (39). 
 Collectively, this data has provided new information about the relationship 
between virus-to-host interactions during viral entry. This research contributes not only to 
the understanding of the fatal JCPyV infection, but it can also be applied to a broader 
understanding of viral pathogenesis and its implications in human disease, ultimately 
leading to the development of effective therapeutics against opportunistic viral 
pathogens. 
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